Goldman initiated coverage on Vor Biopharma with a new price target
$VOR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Goldman initiated coverage of Vor Biopharma with a rating of Neutral and set a new price target of $6.00